Critical design criteria for minimal antibiotic‐free plasmid vectors necessary to combine robust RNA Pol II and Pol III‐mediated eukaryotic expression with high bacterial production yields
- 30 August 2010
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 12 (10) , 818-831
- https://doi.org/10.1002/jgm.1499
Abstract
Background: For safety considerations, regulatory agencies recommend the elimination of antibiotic resistance markers and non‐essential sequences from plasmid DNA‐based gene medicines. In the present study, we analyzed antibiotic‐free (AF) vector design criteria impacting upon bacterial production and mammalian transgene expression.Methods: Both CMV‐HTLV‐I R RNA Pol II promoter (protein transgene) and murine U6 RNA Pol III promoter (RNA transgene) vector designs were studied. Plasmid production yield was assessed through inducible fed‐batch fermentation. RNA Pol II‐directed enhanced green fluorescent protein and RNA Pol III‐directed RNA expression were quantified by fluorometry and quantitative real‐time polymerase chain reaction, respectively, after transfection of human HEK293 cells.Results: Sucrose‐selectable minimalized protein and therapeutic RNA expression vector designs that combined an RNA‐based AF selection with highly productive fermentation manufacturing (>1000 mg/l plasmid DNA) and high‐level in vivo expression of encoded products were identified. The AF selectable marker was also successfully applied to convert existing kanamycin‐resistant DNA vaccine plasmids gWIZ and pVAX1 into AF vectors, demonstrating a general utility for retrofitting existing vectors. A minimum vector size for high yield plasmid fermentation was identified. A strategy for stable fermentation of plasmid dimers with improved vector potency and fermentation yields up to 1740 mg/l was developed.Conclusions: We report the development of potent high yield AF gene medicine expression vectors for protein or RNA (e.g. short hairpin RNA or microRNA) products. These AF expression vectors were optimized to exceed a newly‐identified size threshold for high copy plasmid replication and direct higher transgene expression levels than alternative vectors. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 24 references indexed in Scilit:
- pFARs, Plasmids free of antibiotic resistance markers, display high‐level transgene expression in muscle, skin and tumour cellsThe Journal of Gene Medicine, 2010
- Marker-free plasmids for gene therapeutic applications—Lack of antibiotic resistance gene substantially improves the manufacturing processJournal of Biotechnology, 2010
- Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection systemVaccine, 2009
- Generic plasmid DNA production platform incorporating low metabolic burden seed‐stock and fed‐batch fermentation processesBiotechnology & Bioengineering, 2009
- Transgene expression of transfected supercoiled plasmid DNA concatemers in mammalian cellsThe Journal of Gene Medicine, 2009
- Plasmid DNA vaccine vector design: Impact on efficacy, safety and upstream productionBiotechnology Advances, 2009
- A hybrid CMV-H1 construct improves efficiency of PEI-delivered shRNA in the mouse brainNucleic Acids Research, 2007
- Inducible Escherichia coli fermentation for increased plasmid DNA productionBiotechnology and Applied Biochemistry, 2006
- Using ColE1‐derived RNA I for suppression of a bacterially encoded gene: implication for a novel plasmid addiction systemBiotechnology Journal, 2006
- Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmidGene Therapy, 2001